Halia Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

About Halia Therapeutics About Halia Therapeutics Halia Therapeutics is a clinical-stage biopharmaceutical company focused on treating the root causes of inflammation. Leveraging genetic insights and AI-enabled discovery, Halia is building a robust pipeline of novel therapeutics based on genetic resilience that targets inflammatory pathways in diseases ranging from metabolic disorders to neurodegeneration and hematologic malignancies. Halia's mission is to create data-driven therapies...

About Halia Therapeutics

Halia Therapeutics is a clinical-stage biopharmaceutical company focused on treating the root causes of inflammation. Leveraging genetic insights and AI-enabled discovery, Halia is building a robust pipeline of novel therapeutics based on genetic resilience that targets inflammatory pathways in diseases ranging from metabolic disorders to neurodegeneration and hematologic malignancies.

Halia's mission is to create data-driven therapies that not only extend life but also improve its quality. The company is headquartered in Lehi, Utah, and is actively advancing global partnerships in clinical research, drug discovery, and personalized medicine.

To learn more, visit www.haliatx.com or follow us on LinkedIn and Twitter @HaliaTx.

Media Contact

Taylor Avei 
Director of Business Development
Halia Therapeutics
[email protected]

Investor Contact

Leigh Salvo 
New Street Investor Relations
[email protected]

Logo - https://mma.prnewswire.com/media/2702932/Halia_Therapeutics_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/halia-therapeutics-to-participate-in-the-morgan-stanley-23rd-annual-global-healthcare-conference-302546094.html